No abstract

n-Bu) 2 Sn{4-ClC 6 H 4 C(O)NHO} 2 ] (DBDCT) is a new diorganotin(IV) benzohydroxamate which shows high in vivo antitumor activity with relative low toxicity. An HPLC method for the determination of diorganotin(IV) benzohydroxamate (DBDCT) was first validated in the pharmacokinetic studies in plasma. The rat plasma was deproteinized with methanol that contained acetanilide as the internal standard and then separated. The HPLC assay was carried out using a Diamonsil ODS (4.6 mm×200 mm, 5 µm) column. The mobile phase was methanol and 0.5% trifluoroacetic acid (TFA) in water (30∶70, V/V, pH 3.0) with a flow rate of 1.0 mL•min -1 . The detection wavelength was set at 238 nm. This method was found to be linear within the concentration range of 0.1-25 µg•mL -1 (r＝0.9992). The limit values of quantification and detection were 50 and 10 ng•mL -1 , respectively. The method was used to determine the concentration-time profiles for DBDCT in the plasma after single intravenous administration with different doses to rats (2, 5, 12 mg•kg -1 ). The pharmacokinetics parameter calculations and modeling were carried out using the 3p97 pharmacokinetics software. The results showed that the concentration-time curve of DBDCT in rat plasma could be fitted to the two-component model.

No abstract

No abstract